Mike Dean Referee Wife, Articles I

917-322-2571, Internet Explorer presents a security risk. Operating Status Active. A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms | Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of the Universal Intracellular Targeted Expression (UNITE) nucleic acid immunotherapy platform. J Immunol. immunomic therapeutics crunchbase We currently have 4 wholly-owned oncology programs, with our lead program in Phase 2 clinical studies for GBM. Individuals who thrive in our environment are team-oriented, self-motivated, creative, and persistent. Immunomic Therapeutics, Inc. Biotechnology Research Rockville, MD 2,335 followers A privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms Active, Closed, Last funding round type (e.g. The New Taipei Municipal Hsin Tien Senior High School ( Chinese: ) is a senior high school in Xindian District, New Taipei, Taiwan which was founded in 1992. Headquarters Location. Melissa Kemp UNITE is currently being employed in Phase II clinical trials as a cancer immunotherapy. Immunomic Therapeutics, Inc. is committed to building, developing and retaining a world-class team. Immunomic Therapeutics Receives FDA Fast Track Designation for ITI-3000 mcarey@rxir.com Our company has the capability to successfully plan, design and conduct clinical studies that enable us to establish POC in humans in a timely manner with the underlying capabilities to manufacture clinical trial supplies. Immunomic Therapeutics Inc - Company Profile and News Preclinical data is currently being developed to explore whether the UNITE platform may amplify and activate the immune response in highly immunogenic tumor types and be used to create immune responses to tumor types that otherwise do not provoke an immune response. Immunomic Therapeutics - Crunchbase Company Profile & Funding Stock ticker symbol (e.g. ITI-1001 represents an off-the-shelf cancer immunotherapy approach that leverages ITIs proprietary UNITE platform to target CMV-associated antigens (pp65, IE-1 & gB) in Newly-Diagnosed Glioblastoma Multiforme (GBM).The primary mechanism of action of ITI-1001 is to enable specific presentation of the antigens via the lysosome mediated pathway in the antigen presenting cells (APC).